In8bio, INC 8-K filings

IN8bio reports 100% complete remission in AML patients treated with INB-100 and receives FDA guidance for a registrational trial, while also showing promising results in glioblastoma with INB-200.

IN8bio announced positive clinical trial results for its gamma-delta T cell therapies and its second quarter 2024 financial results, while also disclosing a Nasdaq notification regarding its stock price.

IN8bio reports that 100% of evaluable leukemia patients in a Phase 1 trial of INB-100 achieved durable complete remission at one year, showcasing the potential of their gamma-delta T cell therapy.

IN8bio's INB-200 shows encouraging preliminary results in a Phase 1 study, with 92% of evaluable glioblastoma patients exceeding the standard progression-free survival.

IN8bio announced its first quarter 2024 financial results, highlighting progress in its gamma-delta T cell therapy programs and the advancement of its clinical trials.

IN8bio announced positive clinical trial results for its cancer therapies and secured funding to extend its cash runway into the first quarter of 2025.